male patients ≤ 50 years in their post renal transplant follow-up;

biopsy confirmed prostate cancer;

stable renal function with gfr ≥ 40 ml/min.

patients with metastatic disease;

uncontrolled hyperlipidemia;

proteinuria > 500 mg/day;

biopsy evidence of acute rejection within the past 3 months;

existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator might significantly alter the absorption, distribution, metabolism or excretion of study medication;

patients with mental illness;

inability to cooperate or communicate with the investigator or unable to complete self administered questionnaires.